Literature DB >> 17264850

Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters.

S G Wannamethee1, J Tchernova, P Whincup, G D Lowe, A Rumley, K Brown, L Cherry, N Sattar.   

Abstract

BACKGROUND AND AIM: Adiponectin is considered by many to be part of the 'common soil' linking type 2 diabetes and coronary heart disease (CHD). We examined the relationship between adiponectin and insulin resistance, metabolic, inflammatory and haemostatic risk factors and hepatic function. METHODS AND
RESULTS: The study was carried out in 3640 non-diabetic men aged 60-79 years drawn from general practices in 24 British towns and who were not on warfarin. Adiponectin was associated with waist circumference (inversely), alcohol intake (positively) and physical activity (nonlinearly); no association was seen with cigarette smoking, prevalent CHD or stroke. After adjustment for these factors, adiponectin was significantly inversely associated with insulin resistance, triglyceride, C-reactive protein (but not interleukin 6), tissue plasminogen activator and alanine aminotransferase and positively associated with high-density lipoprotein cholesterol (HDL-cholesterol) and Factor VIII, factors associated with diabetes. No association was seen with cholesterol, smoking, systolic blood pressure or coagulation factors. Risk of the metabolic syndrome decreased significantly with increasing adiponectin.
CONCLUSION: Adiponectin is inversely associated with factors strongly associated with the development of diabetes. Limited associations with the established major risk factors for CHD suggest adiponectin may be a stronger marker of risk for diabetes than for CHD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17264850     DOI: 10.1038/sj.ijo.0803544

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  15 in total

1.  CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers.

Authors:  Sridevi Devaraj; Michael M Swarbrick; Uma Singh; Beverley Adams-Huet; Peter J Havel; Ishwarlal Jialal
Journal:  Am J Clin Pathol       Date:  2008-05       Impact factor: 2.493

Review 2.  Clinical Scenario of the Metabolic Syndrome.

Authors:  Swantje Brede; Georg Serfling; Johanna Klement; Sebastian M Schmid; Hendrik Lehnert
Journal:  Visc Med       Date:  2016-09-19

3.  Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans.

Authors:  J L Beebe-Dimmer; K A Zuhlke; A M Ray; E M Lange; K A Cooney
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-08-10       Impact factor: 5.554

4.  Validation of a metabolite panel for early diagnosis of type 2 diabetes.

Authors:  Tonia C Carter; Dietrich Rein; Inken Padberg; Erik Peter; Ulrike Rennefahrt; Donna E David; Valerie McManus; Elisha Stefanski; Silke Martin; Philipp Schatz; Steven J Schrodi
Journal:  Metabolism       Date:  2016-06-26       Impact factor: 8.694

Review 5.  Cardiac remodeling in obesity.

Authors:  E Dale Abel; Sheldon E Litwin; Gary Sweeney
Journal:  Physiol Rev       Date:  2008-04       Impact factor: 37.312

6.  Green Tea Extract and Catechol-O-Methyltransferase Genotype Modify Fasting Serum Insulin and Plasma Adiponectin Concentrations in a Randomized Controlled Trial of Overweight and Obese Postmenopausal Women.

Authors:  Allison M Dostal; Hamed Samavat; Luis Espejo; Andrea Y Arikawa; Nicole R Stendell-Hollis; Mindy S Kurzer
Journal:  J Nutr       Date:  2015-11-18       Impact factor: 4.798

7.  Evidence of a causal relationship between adiponectin levels and insulin sensitivity: a Mendelian randomization study.

Authors:  He Gao; Tove Fall; Rob M van Dam; Allan Flyvbjerg; Björn Zethelius; Erik Ingelsson; Sara Hägg
Journal:  Diabetes       Date:  2012-12-28       Impact factor: 9.461

8.  A genome-wide association study reveals variants in ARL15 that influence adiponectin levels.

Authors:  J Brent Richards; Dawn Waterworth; Stephen O'Rahilly; Marie-France Hivert; Ruth J F Loos; John R B Perry; Toshiko Tanaka; Nicholas John Timpson; Robert K Semple; Nicole Soranzo; Kijoung Song; Nuno Rocha; Elin Grundberg; Josée Dupuis; Jose C Florez; Claudia Langenberg; Inga Prokopenko; Richa Saxena; Robert Sladek; Yurii Aulchenko; David Evans; Gerard Waeber; Jeanette Erdmann; Mary-Susan Burnett; Naveed Sattar; Joseph Devaney; Christina Willenborg; Aroon Hingorani; Jaquelin C M Witteman; Peter Vollenweider; Beate Glaser; Christian Hengstenberg; Luigi Ferrucci; David Melzer; Klaus Stark; John Deanfield; Janina Winogradow; Martina Grassl; Alistair S Hall; Josephine M Egan; John R Thompson; Sally L Ricketts; Inke R König; Wibke Reinhard; Scott Grundy; H-Erich Wichmann; Phil Barter; Robert Mahley; Y Antero Kesaniemi; Daniel J Rader; Muredach P Reilly; Stephen E Epstein; Alexandre F R Stewart; Cornelia M Van Duijn; Heribert Schunkert; Keith Burling; Panos Deloukas; Tomi Pastinen; Nilesh J Samani; Ruth McPherson; George Davey Smith; Timothy M Frayling; Nicholas J Wareham; James B Meigs; Vincent Mooser; Tim D Spector
Journal:  PLoS Genet       Date:  2009-12-11       Impact factor: 5.917

9.  Association between adiponectin and heart failure risk in the physicians' health study.

Authors:  Luc Djoussé; Jemma B Wilk; Naomi Q Hanson; Robert J Glynn; Michael Y Tsai; J Michael Gaziano
Journal:  Obesity (Silver Spring)       Date:  2013-04       Impact factor: 5.002

Review 10.  Insights into the Genetic Susceptibility to Type 2 Diabetes from Genome-Wide Association Studies of Obesity-Related Traits.

Authors:  Tugce Karaderi; Alexander W Drong; Cecilia M Lindgren
Journal:  Curr Diab Rep       Date:  2015-10       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.